Comparison of immunogenicity and short term reactogencity of MMR vaccine

Comparison of immunogenicity and short term reactogenicity of a local and a WHO approved commercial MMR vaccines in Iranian children and infants

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806252471N1

Enrollment

720

Registered

2010-06-14

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MMR. Need for immunization against measles-mumps-rubella [MMR]

Interventions

Intervention 1: Injecting WHO approved MMR vaccine (control group). Intervention 2: Injecting Iranian MMR Vaccine (case group).

Treatment - Drugs

Injecting WHO approved MMR vaccine (control group)

Injecting Iranian MMR Vaccine (case group)

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Healthy children Exclusion criteria: Incomplete vaccination card, immunodeficiency disease, severe asthma and allergy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Antibody response against Measles, Mumps and Rubella. Timepoint: Start (0), 2, 6 month after vaccination. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Vaccines reactogencity. Timepoint: Immediately and two month after vaccination. Method of measurement: Checking by parents and physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fazel Shokri

Avicenna Research Institute

fazshok@yahoo.com+98 21 2243 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026